DiaMedica Therapeutics (NASDAQ:DMAC - Get Free Report) released its quarterly earnings results on Monday. The company reported ($0.18) earnings per share for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.01), Zacks reports.
DiaMedica Therapeutics Price Performance
NASDAQ:DMAC traded down $0.05 during mid-day trading on Friday, reaching $5.09. The stock had a trading volume of 24,312 shares, compared to its average volume of 70,007. The stock has a 50-day simple moving average of $5.94 and a two-hundred day simple moving average of $5.10. The stock has a market capitalization of $217.65 million, a PE ratio of -9.09 and a beta of 1.52. DiaMedica Therapeutics has a 12 month low of $2.14 and a 12 month high of $6.82.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright lifted their price target on shares of DiaMedica Therapeutics from $7.00 to $10.00 and gave the company a "buy" rating in a research report on Wednesday.
Get Our Latest Stock Analysis on DiaMedica Therapeutics
DiaMedica Therapeutics Company Profile
(
Get Free Report)
DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.
See Also
Before you consider DiaMedica Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DiaMedica Therapeutics wasn't on the list.
While DiaMedica Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
